

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September 2013

(Rs in Lacs)

Particulars	Three months ended 30/09/2013 Unaudited	Preceding three months ended 30/06/2013 Unaudited	Corresponding three months ended 30/09/2012 Unaudited	Half Year ended 30/09/2013 Unaudited	Corresponding Half Year ended 30/09/2012 Unaudited	Previous year ended 31/03/2013 Audited
1						
Income from Operation						
(a) Net Sales/Income from Operations of Excise Duty (Net)	5283.05	5024.12	4776.09	10307.17	9633.48	18721.55
(b) Other Operating Income	12.55	0.29	7.71	12.84	9.25	13.74
Total Income From Operation (Net)	5295.60	5024.40	4783.80	10320.00	9,642.73	18735.29
2						
Expenditure						
a) Consumption of Material Consumed	2989.38	2982.30	2364.85	5971.68	3838.30	10018.2
b) Purchase of Stock In Trade						
c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	-254.36	-449.98	-210.97	-704.34	2051.59	1720.37
d) Employee Benefit Expenses	464.31	400.83	519.73	865.15	1071.87	1736.48
e) Depreciation and Amortisation Expenses	436.16	439.71	430.00	875.87	860.00	1733.84
f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately	1708.03	1771.93	2017.31	3479.96	4085.65	7473.95
Total Expenses	5343.52	5144.79	5120.92	10488.31	11907.41	22682.84
3						
Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(47.92)	(120.39)	(337.12)	(168.31)	(2,264.68)	(3,947.55)
4						
Other Income			0.00			0.00
5						
Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(47.92)	(120.39)	(337.12)	(168.31)	(2,264.68)	(3,947.55)
6						
Finance costs	1326.19	1292.35	1236.29	2618.54	2311.07	4222.44
7						
Profit after Interest but before Exceptional items (5-6)	(1,374.11)	(1,412.74)	(1,573.41)	(2,786.85)	(4,575.75)	(8,169.99)
8						
Exceptional items			0.00			0.00
9						
Profit / (Loss) from ordinary activities before tax	(1,374.11)	(1,412.74)	(1,573.41)	(2,786.85)	(4,575.75)	(8,169.99)
10						
Tax Expenses	40.00	85.00	50	125.00	100.00	349.54
11						
Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,414.11)	(1,497.74)	(1,623.41)	(2,911.85)	(4,675.75)	(8,519.53)
12						
Extraordinary items (net of tax expense) Lakhs)						
13						
Net Profit / (Loss) for the period (11 + 12)	(1,414.11)	(1,497.74)	(1,623.41)	(2,911.85)	(4,675.75)	(8,519.53)
14						
Share of profit / (loss) of associates*						
15						
Minority interest *						
16						
Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,414.11)	(1,497.74)	(1,623.41)	(2,911.85)	(4,675.75)	(8,519.53)
17						
Paid-up equity share capital (Face Value of the Share shall be indicated)	2586.68	2586.68	2586.68	2586.68	2586.68	2586.68
18						
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						16848.8
19 i						
Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						
(a) Basic	(5.47)	(5.79)	(6.28)	(11.26)	(18.08)	(32.94)
(b) Diluted	(5.47)	(5.79)	(6.28)	(11.26)	(18.08)	(32.94)
19 ii						
Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):						
(a) Basic	(5.47)	(5.79)	(6.28)	(11.26)	(18.08)	(32.94)
(b) Diluted	(5.47)	(5.79)	(6.28)	(11.26)	(18.08)	(32.94)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956. Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



A PARTICULARS OF SHAREHOLDING

1	Public Shareholding					
	-No. of Shares	7967057	7944924	7944924	7944924	7944924
	-Percentage of shareholding	30.80%	30.71%	30.71%	30.71%	30.71%
2	Promoters and Promoter Group Shareholding **					
	a) Pledged/Encumbered					
	-No. of shares	15076441	17921907	7378799	7378799	17921907
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	84.23%	100.00%	41.17%	41.17%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	58.28%	69.29%	28.53%	28.53%	69.29%
	b) Non-encumbered					
	-No. of shares	2823333		10543108	10543108	
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	15.77%		58.83%	58.83%	
	-Percentage of Shares (as a % of the total share capital of the Company)	10.92%		40.76%	40.76%	
B	Detail of Investor Compliant		3 months ended (30.09.2013)			
	Pending at the beginning of the quarter			0		
	Received during the quarter			3		
	Disposed of during the quarter			3		
	Remaining unresolved at the end of the quarter			0		

Statement of Assets and Liabilities

Sr. No.	Particulars	30.09.2013	31.03.2013
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	3774.09	3774.09
	(b) Reserves and Surplus	14168.50	17080.35
	Sub-total - Shareholders' funds	17942.59	20854.44
2	Call money against Preference Shares	500.00	0.00
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings	32883.22	30564.47
	(b) Deferred tax liabilities (net)	2502.51	2377.51
	Sub-total - Non-current liabilities	35385.73	32941.98
5	Current liabilities		
	(a) Short-term borrowings	5390.87	5025.68
	(b) Trade payables	3254.80	3927.25
	(c) Other current liabilities	66.10	94.49
	(d) Short-term provisions	369.62	398.02
	Sub-total - Current liabilities	9081.39	9445.44
	TOTAL - EQUITY AND LIABILITIES	62909.71	63241.86
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	32307.84	32841.14
	(b) Non-current investments	13964.07	13964.07
	(c) Long-term loans and advances	2614.25	2397.39
	(d) Other non-current assets	0.64	0.64
	Sub-total - Non-current assets	48886.80	49203.24
2	Current assets		
	(a) Inventories	4929.49	3626.67
	(b) Trade receivables	6694.94	7762.97
	(c) Cash and cash equivalents	272.27	530.93
	(d) Short-term loans and advances	1904.89	1898.24
	(e) Other current assets	221.30	219.81
	Sub-total - Current assets	14022.90	14038.62
	TOTAL - ASSETS	62909.71	63241.86

NOTES :

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 14th November 2013.
- The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
- The previous year/period have been regrouped/rearranged wherever found necessary.
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

For and on behalf of Board of Directors

Place: Indore

Date: 14th November 2013

Vinod Kumar Gupta
Managing Director

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2013

PART - I		(Rs in Lacs)					
Sr. No.	Particulars	Three months ended 30/09/2013 Unaudited	Preceding three months ended 30/06/2013 Unaudited	Corresponding three months ended 30/09/2012 Unaudited	Half Year ended 30/09/2013 Unaudited	Corresponding Half Year ended 30/09/2012 Unaudited	Previous year ended 31/03/2013 Audited
1	Income from Operation						
	(a) Net Sales/Income from Operations (Net of Excise Duty)	7397.83	8070.79	7239.25	15468.62	14398.73	32742.72
	(b) Other Operating Income	191.68	0.83	12.00	192.51	15.17	24.51
	Total Income From Operation (Net)	7589.51	8071.62	7251.25	15661.13	14413.90	32767.23
2	Expenditure						
	a) Cost of Material Consumed	4278.22	4850.39	4184.65	9128.61	7235.34	18508.5
	b) Purchase of Stock In Trade						
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	-402.21	-372.68	-632.30	-774.69	1493.56	901.36
	d) Employee Benefit Expenses	537.03	472.09	652.99	1009.13	1248.09	2128.12
	e) Depreciation and Amortisation Expenses	455.18	456.05	564.32	911.23	1010.37	2299.58
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately	2507.67	2623.15	2806.30	5130.82	5494.57	12606.68
	Total Expenses	7375.90	8029.00	7575.95	15404.90	16481.93	36444.24
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	213.61	42.62	(324.70)	256.23	(2,068.03)	(3,677.01)
4	Other Income						
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	213.61	42.62	(324.70)	256.23	(2,068.03)	(3,677.01)
6	Finance costs	1545.88	1416.31	1598.97	2964.18	2800.41	5584.68
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional Items (5-6)	(1,332.27)	(1,375.68)	(1,923.67)	(2,707.95)	(4,868.44)	(9,261.69)
8	Exceptional items	0.00	5227.10	0.00	5227.10	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(1,332.27)	3,851.42	(1,923.67)	2,519.15	(4,868.44)	(9,261.69)
10	Tax Expenses	40.51	-1228.62	69.66	-1188.12	141.96	1522.05
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(1,372.77)	5,080.04	(1,993.34)	3,707.27	(5,010.39)	(10,783.74)
12	Extraordinary items (net of tax expense Lakhs)		0.00				0.00
13	Net Profit / (Loss) for the period (11 + 12)	(1,372.77)	5,080.04	(1,993.34)	3,707.27	(5,010.39)	(10,783.74)
14	Share of profit / (loss) of associates*						
15	Minority interest *						
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(1,372.77)	5,080.04	(1,993.34)	3,707.27	(5,010.39)	(10,783.74)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2586.68	2586.68	2586.68	2586.68	2586.68	2586.68
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						19078.14
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(5.31)	19.64	(7.71)	14.33	(19.37)	(41.69)
	(b) Diluted	(5.31)	19.64	(7.71)	14.33	(19.37)	(41.69)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(5.31)	19.64	(7.71)	14.33	(19.37)	(41.69)
	(b) Diluted	(5.31)	19.64	(7.71)	14.33	(19.37)	(41.69)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Revised Schedule VI of the Companies Act, 1956.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



PART -II

A PARTICULARS OF SHAREHOLDING						
1	Public Shareholding					
	-Number of Shares	7967057	7944924	7944924	7944924	7944924
	-Percentage of shareholding	30.80%	30.71%	30.71%	30.71%	30.71%
2	Promoters and Promoter Group Shareholding **					
	a) Pledged/Encumbered					
	-Number of shares	15076441	17921907	7378799	7378799	17921907
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	84.23%	100.00%	41.17%	41.17%	100.00%
	-Percentage of Shares (as a % of the total share capital of the Company)	58.28%	69.29%	28.53%	28.53%	69.29%
	b) Non-encumbered					
	-Number of shares	2823333		10543108	10543108	
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	15.77%		58.83%	58.83%	
	-Percentage of Shares (as a % of the total share capital of the Company)	10.92%		40.76%	40.76%	
B Detail of Investor Compliant						
		3 months ended (30.09.2013)				
	Pending at the beginning of the quarter					0
	Received during the quarter					3
	Disposed of during the quarter					3
	Remaining unresolved at the end of the quarter					0

Statement of Assets and Liabilities

Sr. No.	Particulars	30.09.2013	31.03.2013
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	4324.09	4324.09
	(b) Reserves and Surplus	22892.41	19197.94
	Sub-total - Shareholders' funds	27216.50	23522.03
2	Share application money pending allotment	4164.00	1100.00
3	Minority interest *	65.05	65.05
4	Non-current liabilities		
	(a) Long-term borrowings	35015.45	40027.83
	(b) Deferred tax liabilities (net)	2624.29	3754.37
	Sub-total - Non-current liabilities	37639.74	43782.20
5	Current liabilities		
	(a) Short-term borrowings	6465.45	8364.00
	(b) Trade payables	4664.40	5971.64
	(c) Other current liabilities	85.25	196.14
	(d) Short-term provisions	528.72	531.38
	Sub-total - Current liabilities	11743.82	15063.16
	TOTAL - EQUITY AND LIABILITIES	80829.11	83532.44
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	34118.09	48200.30
	(b) Goodwill on consolidation *	13218.17	13218.17
	(c) Non-current investments	2.66	2.66
	(d) Deferred tax assets (net)	61.03	0.00
	(e) Long-term loans and advances	1859.65	1471.54
	(f) Other non-current assets	1430.20	1430.23
	Sub-total - Non-current assets	50689.81	64322.90
2	Current assets		
	(a) Inventories	7617.15	6426.35
	(b) Trade receivables	8136.92	7895.03
	(c) Cash and cash equivalents	3642.64	1049.92
	(d) Short-term loans and advances	10458.11	3578.60
	(e) Other current assets	284.48	259.64
	Sub-total - Current assets	30139.30	19209.54
	TOTAL - ASSETS	80829.11	83532.44

NOTES :

- The above results were reviewed by statutory auditors and audit committee of the company and approved by Board of Directors in their meeting held on 14th November 2013.
 - The unaudited financial results of the subsidiary companies have been consolidated.
 - The Company's one subsidiary company has advised that in view of their major expansion plan scheduled for the current year by adding three IV fluid manufacturing units, no income tax liability is envisaged during the current financial year hence no provision for taxes is required to be made.
 - The Company is engaged in the Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17).
 - The previous year/period have been regrouped/rearranged wherever found necessary.
 - The consolidated financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The key standalone financial results are given below:

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Prev. Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	31.03.2013
1	Income from operations & other income	5,295.60	5,024.40	4,783.80	10,320.00	9,642.73	18,735.29
2	Profit/Loss before tax	(1,374.11)	(1,412.74)	(1,573.41)	(2,786.85)	(4,575.75)	(8,169.99)
3	Profit/Loss after tax	(1,414.11)	(1,497.74)	(1,623.41)	(2,911.85)	(4,675.75)	(8,519.53)

Place: Indore
Date: 14th November 2013

Vinod Kumar Gupta
Managing Director

